CTKB · Cytek Biosciences
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $6.39
Note written ·
Price against the kill line
8.6% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $6.39, on record since 11 November 2026. The shares are up 23.2% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $6.39, over the 52-week intraday high of $6.33 set on 29 October 2026, which would show the shares leading again. Quarterly revenue growth back at or above the 6% pace of the first half of 2026 would point the same way.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 4 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 53.2
- Revenue, change on a year (%)
- +1.8
- Gross margin (%)
- 58.6
- Operating margin (%)
- −15.8
- Free cash flow, four quarters ($M)
- −13.5
- Free-cash-flow yield (%)
- −1.8
All filed numbers
What Cytek Biosciences reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 53.2 | +1.8 | 58.6 | −15.8 |
| first filed | 48.1 | +5.6 | 58.9 | −23.7 |
| first filed | 44.1 | +6.5 | 48.2 | −41.8 |
| first filed | 62.1 | +8.1 | 52.9 | −9.0 |
| first filed | 52.3 | +1.5 | 52.7 | −17.6 |
| first filed | 45.6 | −2.2 | 52.3 | −23.3 |
| Pre-tax income ($M) quarter to 31 December 2025, filed 26 February 2026 | −4.0 |
| Net income ($M) four quarters: −81.2 | −6.1 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +2.2 |
| Operating cash flow ($M) | −6.6 |
| Capital spending ($M) | 6.9 |
| Free cash flow ($M) | −13.5 |
| Cash and short-term investments ($M) | 66.8 |
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) +10.2% on a year | 50.8 |
| Backlog, orders not yet delivered ($M) +8.8% on a year | 49.0 |
| Receivables ($M) | 59.2 |
| Inventory ($M) | 52.4 |
| Shareholders' equity ($M) | 321 |
| Market value ($M) | 764 |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.4 |
| Free-cash-flow yield (%) | −1.8 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 3.4% of shares outstanding sold short, 2.7 days of average trading to cover, −15.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $0 |
The thesis
Cytek Biosciences' revenue growth slowed to 2% in the third quarter of 2026, and product sales fell, so the shares look more likely to lag the S&P 500 than lead it. Fourth-quarter revenue against the $208 million–$211 million full-year outlook settles it.
Cytek reported third-quarter revenue of $53.2 million on 4 November 2026, up from $52.3 million a year earlier. Growth was 6% in the second quarter. The report beat analyst estimates on revenue ($53.229 million against $52.800 million) and on loss per share ($0.05 against $0.08), according to a Benzinga summary. The shares still closed at $5.40 on 5 November 2026, down from $5.88 on 4 November 2026, before recovering to $5.83 on 6 November 2026.
Margin repair is the real improvement. Stephens & Co. kept its Overweight rating on 10 November 2026 and raised its price target to $7. The shares have risen 17.8% over three months, so the market already pays for margin gains and a U.S. academic recovery while product revenue and Asia-Pacific sales shrink.
Bullish and bearish views on Cytek Biosciences, Inc.
The bull case on Cytek Biosciences, Inc. (CTKB), in brief: gross margin is rising. The bear case: growth has slowed to 2%.
Bull case
- Gross margin is rising. GAAP gross margin was 59% in the third quarter versus 53% a year earlier, and adjusted gross margin was 61% versus 55%, per the 4 November 2026 release.
- Recurring revenue keeps gaining share. Recurring revenue was $19.1 million, or 36% of trailing twelve-month revenue versus 33% a year earlier. Service revenue rose to $16.1 million from $14.2 million.
- The U.S. is recovering. A Finviz analysis of the report put U.S. revenue up 12% to $30.4 million. It also reported U.S. academic and government revenue up 38% and high-end analyzer revenue up more than 30%.
- The installed base keeps growing. Cytek added 140 instruments in the quarter for a base of 4,073 as of 30 September 2026. Each adds a buyer for reagents and service.
- The balance sheet is large. Cash, restricted cash and marketable securities were $256.3 million on 30 September 2026, against a quarterly net loss of $6.1 million.
- A covering analyst turned more positive. Stephens & Co. raised its target to $7 on 10 November 2026 and kept an Overweight rating.
Bear case
- Growth has slowed to 2%. Third-quarter revenue rose 2% after 6% in both the first and second quarters. Product revenue fell to $37.2 million from $38.1 million.
- Asia-Pacific and biopharma are shrinking. The Finviz analysis reported Asia-Pacific revenue down 25% and biopharma, distributor and contract research revenue down about 17%, after 22% growth in the second quarter.
- Profit is moving the wrong way. Adjusted EBITDA was $0.7 million versus $2.5 million a year earlier. Operating expenses rose 8% to $39.6 million, and general and administrative costs rose 14% on litigation. The Finviz analysis reported that adjusted EBITDA guidance moved from positive to around break-even.
- The top of the outlook was cut. Cytek narrowed 2026 revenue guidance to $208 million–$211 million from $207 million–$212 million on 4 November 2026. The Finviz analysis calculates that the range requires fourth-quarter revenue of roughly $62.5 million–$65.5 million, well above the third quarter's $53.2 million.
- Patent damages remain unresolved. The 21 August 2026 jury awarded Beckman Coulter $20 million in lost profits and $36 million in royalties on one claim. Cytek has filed post-verdict motions and may appeal.
Price setup
The shares closed at $5.76 on 11 November 2026. That is 9.0% below the 52-week intraday high of $6.33 set on 29 October 2026. The 50-day average of the adjusted closes was $5.46 and the 200-day average was $4.67 as of 11 November 2026, so the shares trade above both. The 52-week closing low was $3.35 on 14 May 2026. The three-month change was 17.8%, measured from the $4.89 close on 13 August 2026.
After the 4 November 2026 report, the shares closed at $5.40 on 5 November 2026, then $5.83 on 6 November 2026, $5.89 on 9 November 2026, $5.79 on 10 November 2026 and $5.76 on 11 November 2026. The earlier October rally has not been regained: the high of $6.33 came a week before the report.
SEC Form 4 filings dated 20 August 2026 show option exercises by the chief executive, chief financial officer, chief technology officer and three directors on 18 August 2026, with shares withheld for tax at $4.67. No open-market insider sales appear in the filings listed since then.
Catalysts ahead
- 17 November 2026: Stephens Annual Investment Conference fireside chat with Cytek's chief executive and chief financial officer. Management can explain how the fourth quarter reaches the $208 million–$211 million full-year outlook after third-quarter revenue growth of 2%.
- ~March 2027 (est.): Fourth-quarter and full-year 2026 results (date not yet announced). Shows whether quarterly revenue growth returns to the 6% pace of the first half and whether the full-year outlook was met.
What would change the view
A daily close above $6.39, over the 52-week intraday high of $6.33 set on 29 October 2026, which would show the shares leading again. Quarterly revenue growth back at or above the 6% pace of the first half of 2026 would point the same way.
What it trades with
Cytek sells flow cytometry instruments, reagents, service and software to academic, government and pharmaceutical researchers. Its results track research-funding conditions, and the third quarter split on that line: U.S. academic and government demand rose while biopharma and Asia-Pacific demand fell. Research-tool peers such as 10x Genomics and Pacific Biosciences report on the same budgets, and weak results from either would bear on Cytek's instrument line. The shares trade on a US exchange.
The evidence, claim by claim (8)
- Third-quarter 2026 revenue was $53.2 million, up 2% from $52.3 million; product revenue fell to $37.2 million from $38.1 million and service revenue rose to $16.1 million from $14.2 million. Cytek Q3 2026 results release (8-K Exhibit 99.1) · as of
- Recurring revenue was $19.1 million in the quarter and 36% of trailing twelve-month revenue, up from 33% a year earlier. Cytek Q3 2026 results release (8-K Exhibit 99.1) · as of
- GAAP gross margin was 59% versus 53% a year earlier; operating expenses rose 8% to $39.6 million; net loss was $6.1 million versus $5.5 million; adjusted EBITDA was $0.7 million versus $2.5 million. Cytek Q3 2026 results release (8-K Exhibit 99.1) · as of
- Cytek narrowed 2026 revenue guidance to $208 million–$211 million from $207 million–$212 million; cash, restricted cash and marketable securities were $256.3 million at 30 September 2026, down from $262.0 million at 30 June 2026. Cytek Q3 2026 results release (8-K Exhibit 99.1) · as of
- Installed base reached 4,073 Cytek instruments, with 140 units added in the third quarter. Cytek Q3 2026 results release (8-K Exhibit 99.1) · as of
- U.S. revenue rose 12% to $30.4 million while Asia-Pacific revenue fell 25% and biopharma, distributor and contract research revenue fell about 17%. Finviz analysis of Cytek Q3 2026 results · as of
- Q3 loss per share of $0.05 beat the $0.08 loss estimate and revenue of $53.229 million beat the $52.800 million estimate. Benzinga earnings summary headline · as of
- Stephens & Co. maintained its Overweight rating on Cytek and raised its price target to $7. Stephens & Co. rating headline · as of
Sources
- Cytek Biosciences, Inc. - Form 8-K - FY2026 · sec.gov
- Cytek Biosciences, Inc. - Form 10-Q - FY2026 · sec.gov
- Cytek beats on a gross margin surge but slowing growth and a fading EBITDA outlook leave a rallied stock little room for error · finviz.com
- Cytek Biosciences reports third quarter 2026 financial results · finviz.com
Related · shared themes
ADPT
Adaptive Biotechnologies
Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter…
AXGN
Axogen
Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest…
CSTL
Castle Biosciences
Castle Biosciences raised 2026 revenue guidance to $385–395 million and held its 50–52% TissueCypher volume growth plan; the fourth-quarter…
DXCM
DexCom
Dexcom's raised 2026 outlook and 25.3% third-quarter operating margin give the shares a modest edge after a diabetes-device sell-off erased…
See also · stocks to watch